Heinz Ludwig, MD, PhD, of Wilhelminen Cancer Research Institute, Vienna, Austria, talks about the importance and advantages of supportive care for patients with multiple myeloma (MM). Dr Wilhelminen discusses the new advances for prophylaxis, particularly thromboprophylaxis. Secondly, he discusses the risks of cardiotoxicity caused by many MM drugs and how to supportively care for patients. Finally, Dr Wilhelminen discusses thrombotic microangiopathy, which he says is considered an emergency state. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.